HJLI - Hancock Jaffe Laboratories, Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
0.9799
+0.0111 (+1.15%)
At close: 3:31PM EDT
Stock chart is not supported by your current browser
Previous Close0.9688
Open1.0000
Bid0.9700 x 900
Ask1.0900 x 1100
Day's Range0.9700 - 1.1000
52 Week Range0.8700 - 3.5670
Volume214,823
Avg. Volume221,125
Market Cap13.859M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.1980
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • ACCESSWIRE9 hours ago

    Hancock Jaffe Principal Investigator Dr. Jorge Hernando Ulloa to Present New 90 Day VenoValve Data at the Second Annual Society of Vascular and Endovascular Surgery Congress of Central America and the Caribbean On July 25, 2019

    IRVINE, CA / ACCESSWIRE / July 19, 2019 / Hancock Jaffe Laboratories, Inc. (Nasdaq: HJLI, HJLIW), a developer of medical devices that restore cardiac and vascular health, announced today that on Thursday, July 25, 2019, Dr. Jorge Hernando Ulloa, Principal Investigator for HJLI’s first-in-man VenoValve study in Bogota, Colombia, will present new 90 day VenoValve data at the Second Annual Society of Vascular and Endovascular Surgery Congress of Central America and the Caribbean. The conference is taking place July 25 to July 27 in the Dominican Republic. In conjunction with Dr. Ulloa's presentation, on July 25, 2019, at 11:00 am Eastern time, Dr. Marc H. Glickman, Hancock Jaffe's Senior Vice President and Chief Medical Officer, and Mr. Robert A. Berman, Hancock Jaffe's Chief Executive Officer, will host a webcast and conference call to present select slides from Dr. Ulloa's presentation and to answer any shareholder questions about the VenoValve.

  • ACCESSWIRE22 days ago

    Hancock Jaffe Reports Early Positive Results For CoreoGraft Animal Feasibility Study

    IRVINE, CA / ACCESSWIRE / June 27, 2019 / Hancock Jaffe Laboratories, Inc. (NASDAQ: HJLI, HJLIW), a developer of medical devices that restore cardiac and vascular health, today provided an update on the status of its CoreoGraft animal feasibility study. There have been no device failures in eight animal test subjects where CoreoGrafts have been implanted as heart bypass grafts, with one group observed at 30 days, and another group observed at 45 days post-surgery. In particular, the CoreoGrafts have showed no signs of thrombosis, aneurysmal degeneration, neointimal hyperplasia, stenosis, changes in the lumen, or other problems that are known to plague saphenous vein grafts ("SVGs") and attempts by others to create small caliber (3 mm and 4 mm) grafts.

  • ACCESSWIRE25 days ago

    Primary Investigator Dr. Jorge Hernando Ulloa Reports New and Updated VenoValve Data at C3 Global Conference

    IRVINE, CA / ACCESSWIRE / June 24, 2019 / Hancock Jaffe Laboratories, Inc. (NASDAQ: HJLI, HJLIW), a developer of medical devices that restore cardiac and vascular health, announced today that on Sunday, June 23, 2019, Dr. Jorge Hernando Ulloa, the Primary Investigator for HJLI's first-in-human VenoValve study in Bogota, Colombia, reported new and updated data for Hancock Jaffe's first-in-human VenoValve study at the 2019 C3 Global Conference in Orlando, Florida. Dr. Ulloa's report indicated that for the first five VenoValve patients, VCSS scores, a measurement of venous disease severity graded by the clinician, have improved an average of forty-six (46%) compared to Pre-VenoValve levels.

  • ACCESSWIRE29 days ago

    Hancock Jaffe Hires Brian Roselauf as Director of Research and Development

    IRVINE, CA / ACCESSWIRE / June 20, 2019 / Hancock Jaffe Laboratories, Inc. (NASDAQ: HJLI, HJLIW), a developer of medical devices that restore cardiac and vascular health, today announced that Brian Roselauf will be joining the company as its Director of Research and Development. Mr. Roselauf will join Hancock Jaffe on June 24, 2019, and will initially focus on design verification and validation activities to prepare for the filing of the Investigational Device Exemption ("IDE") application for the U.S. pivotal trial for HJLI's VenoValve. Brian Roselauf brings 16 years of engineering product development experience and a track record of bringing concepts to commercialization within large publicly traded companies as well as startups.

  • ACCESSWIRElast month

    Hancock Jaffe Primary Investigator Dr. Jorge Hernando Ulloa to Present VenoValve Report at the Venous Summit at the C3 Global Conference

    VenoValve Presentation on June 23, 2019 in Orlando, Florida IRVINE, CA / ACCESSWIRE / June 19, 2019 / Hancock Jaffe Laboratories, Inc. (NASDAQ: HJLI, HJLIW), a developer of medical devices that restore ...

  • What Kind Of Investor Owns Most Of Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI)?
    Simply Wall St.last month

    What Kind Of Investor Owns Most Of Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI)?

    A look at the shareholders of Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI) can tell us which group is most powerful...

  • ACCESSWIRElast month

    Hancock Jaffe Successfully Completes VenoValve Implantation for First-in-Human Study

    IRVINE, CA / ACCESSWIRE / June 13, 2019 / Hancock Jaffe Laboratories, Inc. (NASDAQ: HJLI, HJLIW), a developer of medical devices that restore cardiac and vascular health, has successfully implanted the VenoValve in an additional patient. Six out of the ten patients that are to be a part of the initial phase of HJLI's first-in-human Bogota study have now been successfully implanted. Dr. Marc H. Glickman, Hancock Jaffe's Senior Vice President and Chief Medical Officer, who was present at the surgery in Bogota, Colombia stated, "The VenoValve surgery went exceptionally well.

  • ACCESSWIRElast month

    Hancock Jaffe Announces Pricing of Public Offering of Common Stock

    IRVINE, CA / ACCESSWIRE / June 12, 2019 / Hancock Jaffe Laboratories, Inc. (NASDAQ: HJLI, HJLIW), a developer of medical devices that restore cardiac and vascular health, today announced the pricing of its public offering of 3,615,622 shares of its common stock at a price to the public of $1.07 per share, for expected total gross proceeds of approximately $3.9 million, before deducting placement agent fees and other offering expenses payable by the company. The company intends to use these proceeds to fund the continued development of its two lead products and for working capital and general corporate purposes. Alexander Capital, LP is acting as the sole placement agent for the offering.

  • ACCESSWIRElast month

    Hancock Jaffe Reports Early Positive Results from First-In-Human VenoValve Study

    IRVINE, CA / ACCESSWIRE / June 7, 2019 / Hancock Jaffe Laboratories, Inc. (NASDAQ: HJLI, HJLIW), a developer of medical devices that restore cardiac and vascular health, today announced early positive results from its first-in-human VenoValve Study in Bogota, Colombia. Deep venous reflux has been significantly reduced in 4 out of the first 5 patients that have received VenoValves. Reflux is the primary end point for HJLI's ongoing VenoValve trial and is the main cause of severe, chronic venous insufficiency ("CVI") of the deep vein system.

  • ACCESSWIRE2 months ago

    Hancock Jaffe Enrolls Two Additional Patients for First-in-Human VenoValve Study

    IRVINE, CA / ACCESSWIRE / June 3, 2019 / Hancock Jaffe Laboratories, Inc. (NASDAQ: HJLI, HJLIW), a developer of medical devices that restore cardiac and vascular health, announced today that it has enrolled two additional patients for its VenoValve® first-in-human study in Bogota, Colombia. HJLI expects to implant VenoValves in the two additional patients by the end of June, 2019. Robert Berman, Hancock Jaffe's Chief Executive Officer stated, "We have now enrolled seven patients for our first-in-human Bogota trial.

  • ACCESSWIRE2 months ago

    Hancock Jaffe to Present VenoValve Case Management Report at Expert Venous Management Conference on June 7, 2019

    IRVINE, CA / ACCESSWIRE / May 28, 2019 / Hancock Jaffe Laboratories, Inc. (NASDAQ: HJLI, HJLIW), a developer of medical devices that restore cardiac and vascular health, will report initial data on the first five patients that received VenoValves as part of the first-in-human study in Bogota, Colombia, and will present a case management report at the Expert Venous Management ("EVM") Conference at the Englewood Hospital Medical Center in Englewood, New Jersey on June 7, 2019. The Hancock Jaffe presentation at the EVM conference will be delivered by Dr. Jorge Hernando Ulloa, the primary investigator for Hancock Jaffe's first-in-human VenoValve trial in Bogota, Colombia.

  • ACCESSWIRE2 months ago

    Hancock Jaffe Announces Retirement of Board Chairman Yury Zhivilo

    IRVINE, CA / ACCESSWIRE / May 24, 2019 / Hancock Jaffe Laboratories, Inc. (NASDAQ: HJLI, HJLIW), a developer of medical devices that restore cardiac and vascular health, has announced that its Chairman, Yury Zhivilo, is retiring from its board of directors. Mr. Zhivilo first became interested in Hancock Jaffe when at age 41, he was in need of a heart valve replacement surgery. Following that experience he made a significant investment in Hancock Jaffe both financially and with his time.

  • ACCESSWIRE2 months ago

    Hancock Jaffe Expands CoreoGraft Feasibility Study

    IRVINE, CA / ACCESSWIRE / May 21, 2019 / Hancock Jaffe Laboratories, Inc. (NASDAQ: HJLI, HJLIW), a developer of medical devices that restore cardiac and vascular health, has announced the expansion of its feasibility study for the CoreoGraft. The pre-clinical study has been expanded to include additional animals and a longer term. One group of new test subjects will be monitored for up to 90 days, and the other for up to 180 days.

  • Jazz Pharma (JAZZ) Q1 Earnings and Sales Beat Estimates
    Zacks2 months ago

    Jazz Pharma (JAZZ) Q1 Earnings and Sales Beat Estimates

    Jazz Pharmaceuticals (JAZZ) reports encouraging first-quarter 2019 earnings and revenues and maintains its guidance for 2019.

  • Small Drug Stocks Outlook: Near-Term Prospects Encouraging
    Zacks2 months ago

    Small Drug Stocks Outlook: Near-Term Prospects Encouraging

    Small Drug Stocks Outlook: Near-Term Prospects Encouraging

  • ACCESSWIRE3 months ago

    Hancock Jaffe Announces Successful Third Implantation for CoreoGraft Study at Texas Heart Institute

    IRVINE, CA / ACCESSWIRE / May 1, 2019 / Hancock Jaffe Laboratories, Inc. (NASDAQ: HJLI, HJLIW), a developer of medical devices that restore cardiac and vascular health, has announced the successful third implantation of its CoreoGraft® pre-clinical feasibility study at the Texas Heart Institute. Bypasses using the CoreoGraft have now been successfully completed in all three test subjects. Following the surgery, flow rates were excellent as measured with Transonic probes.

  • ACCESSWIRE3 months ago

    Hancock Jaffe Mourns the Loss of Director Marc Robins

    IRVINE, CA / ACCESSWIRE / April 30, 2019 / Hancock Jaffe Laboratories, Inc. (Nasdaq: HJLI, HJLIW), a developer of medical devices that restore cardiac and vascular health, announces the passing of its director, Marc Robins. Mr. Robins passed away from complications from chronic venous insufficiency. Robert Berman, Hancock Jaffe's Chief Executive Officer stated, ''It is ironic that Marc lost his life to the same disease that our VenoValve is being developed to address.

  • ACCESSWIRE3 months ago

    Hancock Jaffe Successfully Completes Four VenoValve Implantations for First-in-Human Study

    IRVINE, CA / ACCESSWIRE / April 11, 2019 / Hancock Jaffe Laboratories, Inc. (NASDAQ: HJLI, HJLIW), a developer of medical devices that restore cardiac and vascular health, has successfully implanted VenoValves in four additional patients for its first-in-human study in Bogota, Colombia. Robert Berman, Hancock Jaffe's Chief Executive Officer stated, "It is amazing to observe these surgeries, and then watch our patients get up and walk less than two hours after the procedure. The first phase of the first-in-human Colombian study will include 5 to 10 patients who suffer from severe, chronic venous insufficiency (CVI) of the deep vein system, a condition that occurs when the valves in the veins of the venous system of the leg are injured or destroyed, causing blood to flow backwards (reflux) and pool in the lower extremities, and resulting in increased venous pressure (venous hypertension).

  • ACCESSWIRE4 months ago

    Hancock Jaffe Enrolls Four Additional Patients for First-in-Human VenoValve Study

    IRVINE, CA / ACCESSWIRE / March 21, 2019 / Hancock Jaffe Laboratories, Inc. (HJLI), a developer of medical devices that restore cardiac and vascular health, has enrolled four additional patients for its VenoValve first-in-human study in Bogota, Colombia. HJLI expects to implant VenoValves in the four additional patients by the end of April 2019. Robert Berman, Hancock Jaffe's Chief Executive Officer stated, ''We continue to make progress with our VenoValve first-in-human study and are excited to get these implantations underway so that we can continue to receive the feedback and accumulate the data that we need for our U.S. pivotal trial.

  • ACCESSWIRE4 months ago

    Hancock Jaffe Announces Successful Start to CoreoGraft Study at Texas Heart Institute

    IRVINE, CA / ACCESSWIRE / March 18, 2019 / Hancock Jaffe Laboratories, Inc. (NASDAQ: HJLI, HJLIW), a developer of medical devices that restore cardiac and vascular health, today announced the successful start of its CoreoGraft® pre-clinical feasibility study at the Texas Heart Institute. Bypasses using the CoreoGraft have now been successfully completed in two test subjects. Following the surgeries, flow rates were excellent as measured with Transonic probes.

  • ACCESSWIRE4 months ago

    These Four Healthcare Stocks Could Test March Highs

    Given that the success of the healthcare industry is dependent on companies meeting the demands of patients who simply want to live healthy lives, any company taking a patient-centric focus to their healthcare framework has seen impressive gains in the first few months of 2019. Investors looking for potential opportunities could benefit from keeping tabs on the healthcare industry. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Hancock Jaffe Laboratories Inc (HJLI), Kitov Pharmaceuticals Ltd (KTOV), and Auris Medical Holding AG (EARS) are 4 healthcare companies heating up on Thursday.

  • ACCESSWIRE4 months ago

    Hancock Jaffe Completes $2.7 Million Private Placement of Common Stock

    IRVINE, CA / ACCESSWIRE / March 13, 2019 / Hancock Jaffe Laboratories, Inc. (NASDAQ: HJLI, HJLIW), a developer of medical devices that restore cardiac and vascular health, has closed a private placement of 2,360,051 shares of its common stock for aggregate gross proceeds of approximately $2.7 million with various accredited investors, including participation by a member of HJLI's management. The company intends to use these proceeds to fund the continued development of its two lead products and for working capital and general corporate purposes. "In advance of key milestones including preliminary data for our VenoValve® first in-human study, and our CoreoGraft® feasibility study, we wanted to strengthen our balance sheet and extend our operational runway," said Robert Berman, Hancock Jaffe's Chief Executive Officer.

  • GlobeNewswire5 months ago

    Hancock Jaffe Successfully Starts First-in-Human VenoValve Study

    Hancock Jaffe Laboratories, Inc. (Nasdaq: HJLI, HJLIW), a Company specializing in medical devices that restore cardiac and vascular health, today announced the successful start of its VenoValve® first-in-human study in Bogota, Colombia. The patient was walking the day after the surgery, the VenoValve appears to be functioning as it should, and the patient shows no early signs of thrombosis, reflux, or other adverse events. Robert Berman, Hancock Jaffe’s Chief Executive Officer stated, “We are so excited to get our VenoValve study underway and are thrilled that the first patient is doing so well.

  • GlobeNewswire6 months ago

    Hancock Jaffe Announces Objectives for Upcoming CoreoGraft Study

    Hancock Jaffe Laboratories, Inc. (Nasdaq: HJLI, HJLIW), a Company specializing in medical devices that restore cardiac and vascular health, today announced its objectives for its upcoming CoreoGraft® study at the Texas Heart Institute. HJLI expects to provide an update after the first implantation. Provided that the study is successful, Hancock Jaffe would then seek a Pre-FDA meeting to discuss the additional pre-clinical testing that will be necessary for in-human trials.

  • GlobeNewswire6 months ago

    Dr. Marc H. Glickman to Present at 6th Israeli Vascular Access Conference

    Hancock Jaffe Laboratories, Inc. (Nasdaq: HJLI, HJLIW), a Company specializing in medical devices that restore cardiac and vascular health, today announced that Dr. Marc H. Glickman, HJLI's Chief Medical Officer, will be presenting at the 6th Israeli Vascular Access Conference in Herzlia, Israel on January 16, 2019. "There are many factors involved in gaining regulatory approval and market acceptance for medical devices, including having key opinion leaders on board, and having practitioners validate the clinical need for your products," said Robert Berman, Hancock Jaffe’s CEO.